Up-dosing of nivolumab may induce serious immune-related adverse events

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e141-e142. doi: 10.1111/jdv.17701. Epub 2021 Oct 5.

Authors

K Takamoto¹, T Komori¹, Y Ishida¹, N Kambe¹, K Kabashima¹

Affiliation

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 34551172
DOI: 10.1111/jdv.17701

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune System Diseases*
Nivolumab / adverse effects

Substances

Antineoplastic Agents, Immunological
Nivolumab